NASDAQ
OMDA
Last Price
US $24.37
Valuation
Financial
Performance
Cash flow to debt coverage
Omada Health carries no debt; cash flow comfortably covers obligations.
Free cash flow growth
Omada Health's free cash flow has increased -144.50% from $-38.04M last year to $16.93M, signaling increasing performance
Debt-to-equity ratio
Omada Health's debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.
Debt-to-equity trend
Omada Health's debt has decreased relative to shareholder equity from 0.47 last year to 0.00 today, signaling strengthened financials
Net debt to EBITDA
Omada Health has a net cash position, so leverage is healthy.
Interest coverage
Omada Health earns at least as much interest as it pays. Interest obligations are fully covered.
Profit margin growth
Omada Health's profit margin has increased (-105.01%) in the last year from -27.76% to 1.39%, signaling increasing performance
Current ratio
Omada Health's short-term assets of $272.93M exceed its short-term liabilities of $75.73M
Return on assets
Omada Health's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization
Return on equity
Omada Health's return on equity of 1.84%, is lower than 15.00%, indicating bad performance
Earnings quality
Omada Health's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Earnings stability
Omada Health has insufficient public price history to evaluate earnings stability.
Positive free cash flow
Omada Health has positive free cash flow, indicating the company generates cash after capital expenditures
Free cash flow yield
Omada Health has a free cash flow yield of 1.14%, which is below the 2.00% threshold, indicating limited cash return relative to market value
Earnings growth
Omada Health's yearly earnings has increased -72.89% since last year from $-47.14M to $-12.78M, signaling increasing performance
Revenue growth
Omada Health's yearly revenue has increased 53.24% since last year from $169.80M to $260.21M, signaling increasing performance
Return on invested capital
ROIC -0.18% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.
3-year revenue CAGR
Omada Health's 3-year revenue CAGR of 42.89% is positive, indicating growing revenue over the past 3 years
Revenue consistency
Omada Health has insufficient public price history to evaluate revenue consistency.
Return on equity consistency
Omada Health has insufficient public price history to evaluate ROE consistency.
Cash Flow Valuation (DCF)
Omada Health has insufficient data to evaluate this check.
Earnings yield (TTM)
Omada Health has an earnings yield of 0.29%, which is below the 4.00% threshold, indicating the stock may be expensive relative to its earnings
EBITDA Valuation
Omada Health is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model
EV/EBITDA (FY)
Omada Health has negative or missing EBITDA, making EV/EBITDA ratio unreliable
PEG ratio (TTM/FY)
Omada Health has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Price-to-book ratio (FY)
Omada Health has a price-to-book ratio of 5.90x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value
Price-to-sales ratio (TTM)
Omada Health has a price-to-sales ratio of 4.82x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue
Profit margin
Current Ratio
Capital Returns
1.84%
Return on equity
ROIC: -0.18%
Valuation History
358.9X
Price to Earnings
EV/EBITDA: 104.4X
Cash flow
Profit margin
-
Fair Value
Market $24.37
—
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.